Skip to main content
. 2023 Feb 1;55(2):333–346. doi: 10.1038/s12276-023-00929-x

Fig. 1. A p62 ligand prevents systemic inflammation and mortality in vivo.

Fig. 1

a, b Survival of mice for 120 h after injection with LPS (28 mg/kg) and pretreatment for 2 h with ATB1021 (20 mg/kg) (a, n = 4) or pre- and posttreatment for 2 and 1 h, respectively, with ATB1021 (20 mg/kg) (b, n = 7–8). Flowcharts of the experiments are shown. c Survival of control or ATB1021-treated mice 120 h after CLP (n = 7). Flowcharts of the experiments are shown. d Body weight observed for 72 h in vehicle- or ATB1021-treated and LPS-injected mice (n = 6). e–g Quantitative PCR analysis of Il1b (e) and Il6 (f) mRNA levels and the IL-6 protein level (g) in lung and spleen tissues from mice treated with vehicle or ATB1021 for 2 h and injected with LPS (14 mg/kg) for 6 h (n = 4–6). h, i H&E-stained images (h) and inflamed areas (i, n = 3) in the lungs of mice treated with vehicle or ATB1021 (20 mg/kg) and injected with LPS (14 mg/kg). Flowcharts of the experiments are shown with means ± SEM (e–g, i). The log-rank (Mantel‒Cox) test (a–c), Mann‒Whitney U test (e, f, i), or two-tailed Student’s t test (g) was used to determine statistical significance. LPS lipopolysaccharide, CLP cecal ligation and puncture. *p < 0.05, **p < 0.01, ***p < 0.001.